Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Szu-Yuan Wu, Wan-Ming Chen, Yi-Chan Chen, Ming-Feng Chiang, Ming-Che Lee, Ruey-Shyang Soong

研究成果: 雜誌貢獻文章同行評審

6 引文 斯高帕斯(Scopus)

摘要

PURPOSE: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

METHODS: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.

RESULTS: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).

CONCLUSION: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.
原文英語
文章編號101393
頁(從 - 到)101393
期刊Diabetes and Metabolism
49
發行號1
早期上線日期9月 2022
DOIs
出版狀態已發佈 - 1月 2023

ASJC Scopus subject areas

  • 內分泌
  • 內科學
  • 內分泌學、糖尿病和代謝

指紋

深入研究「Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus」主題。共同形成了獨特的指紋。

引用此